Full Press Release Details
National Research Council and Lexaria Bioscience Commence
Kelowna, British Columbia July 20, 2017 Lexaria Bioscience
Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces the start
of laboratory work under its collaborative research program with the National
Research Council of Canada ( NRC ), following the completion of preparation
initiatives announced on March 14, 2017.
As earlier reported, several studies will be initiated in the
coming months designed to optimize Lexaria s patented technology enabling
delivery of lipophilic active agents within foods, beverages, capsules and other
ingestible formats. These studies will investigate lipophilic active agent
classes including cannabinoids, vitamins, NSAIDs, and nicotine.
Advanced analytical techniques including mass spectrometry and
nuclear magnetic resonance testing will be used to evaluate the chemical nature
of the molecular association that Lexaria s technology is believed to form
between lipophilic active agents and the flavor and delivery enabling fatty acid
agents that are integral to Lexaria s formulation methodologies. Practical
applications of this work could include further broadening or strengthening of
Lexaria s intellectual property portfolio and may also provide the foundation
for new commercial arrangements.
We are delighted to have commenced formulation development and
characterization work together with the NRC, stated John Docherty, president of
Lexaria Bioscience. The NRC team has extensive knowledge and experience in the
field of lipid based delivery systems relating to pharmaceutical products,
natural health products and functional foods. This collaboration will
significantly assist Lexaria in further developing and characterizing its IP
Additional information will be released upon completion and
interpretation of test results.
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive technology that promotes healthier ingestion
methods, lower overall dosing and higher effectiveness of lipophilic active
molecules. Lexaria has multiple patents pending in over 40 countries around the
world and was granted its first patents in the USA and in Australia related to
edible forms of cannabinoids. Lexaria s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. www.lexariabioscience.com
For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-Corp-106280556370600/)
and Twitter (https://twitter.com/lexariacorp)
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional stock warrants or stock options will be exercised. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria s
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPovaTM products are not intended to
diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.